Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Laser Vision Correction (LVC) Overview

This excerpt taken from the EYE 8-K filed Feb 13, 2007.

Laser Vision Correction (LVC) Overview

LVC sales grew 76.9 percent versus 2005 to $216.9 million, reflecting the full year benefit of the May 2005 VISX acquisition, growth in CustomVue™ procedures, and strong international system sales.  On a pro forma basis, LVC sales grew 6.9 percent.  Fourth-quarter LVC sales declined 4.5 percent, reflecting primarily fewer system sales versus the year-ago period when the company was conducting the U.S. rollout of Iris Registration technology.  The impact of foreign currency contributed an increase of 0.3 percent and 0.7 percent for the year and fourth quarter, respectively.  Below are LVC sales highlights.  Growth rates reflect comparisons to the same period in 2005 and include the impacts of foreign currency.

·                  Procedures and related sales grew 104.7 percent to $144.3 million, reflecting the VISX acquisition and increased global penetration of CustomVueä procedures.  On a pro forma basis, procedure and related sales grew 12.0 percent.  Fourth-quarter procedure sales grew 14.7 percent.

·                  For 2006, 59.5 percent of the company’s U.S. procedures were wavefront-guided CustomVueä procedures, and its U.S. procedure volume was unchanged versus 2005.

·                  International CustomVue™ procedures gained momentum throughout the year and accounted for approximately 10 percent of the company’s total 2006 procedure sales.  In the fourth quarter, international procedure sales were $4.5 million, of which approximately 80 percent were CustomVueä procedures, representing a 90 percent increase versus the same period one year ago and a 21 percent increase versus the third quarter of 2006.



·                  System sales rose 46.8 percent to $40.1 million, reflecting the VISX acquisition and subsequent execution of AMO’s international expansion strategy.  On a pro forma basis, system sales rose 1.9 percent.  Fourth-quarter system sales declined 34.6 percent, reflecting U.S. rollout of Iris Registration technology in the year-ago period.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki